Overview

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Status:
Terminated

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

This was a pivotal trial to determine whether LX201 reduces the likelihood of a graft rejection episode following corneal transplantation in patients at high immunological risk for rejection.

Phase:

Phase 3

Details

Lead Sponsor:

Lux Biosciences, Inc.

Treatments:

Cyclosporine
Cyclosporins